RCT: Effect of spironolactone on diastolic function and exercise capacity in diastolic heart failure (Aldo-DHF)
Source: JAMA
Area: News
Diastolic heart failure (heart failure with preserved ejection fraction) is a common condition affecting more than half of the total heart failure population but without established therapy. Furthermore, aldosterone stimulation may contribute to its progression.
The Aldo-DHF trial, a multicentre, prospective, randomised, double-blind, placebo-controlled trial, evaluated the effect of long-term spironolactone on diastolic function and exercise capacity in patients with diastolic heart failure.
The study randomised 422 ambulatory patients (mean age, 67 years; 52% female) with ch...
Source: NeLM - Cardiovascular Medicine - February 27, 2013 Category: Cardiology Source Type: news
Heart Failure Drug May Only Help Heart's Function, Not Symptoms
Spironolactone didn't boost treadmill test results, quality of life in one form of condition, study finds (Source: WebMD Health)
Source: WebMD Health - February 26, 2013 Category: Consumer Health News Source Type: news
Spironolactone Disappoints in Preserved-EF HF: Aldo-DHFSpironolactone Disappoints in Preserved-EF HF: Aldo-DHF
Aldosterone blockade didn't produce the outcomes that matter most to patients, despite one benefit in the 422-patient study that was at least encouraging. A large mortality trial is on the way. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 26, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
Mixed Results For Spironolactone In Heart Failure With Preserved Ejection Fraction
Although the mineralocorticoid receptor antagonists (MRAs) spironolactone and eplerenone (Inspra, Pfizer) have been shown to be beneficial in patients with heart failure (HF) with reduced ejection fraction (EF), their role in heart failure patients with preserved EF has not been tested until now. Now the results of the Aldo-DHF (Aldosterone Receptor Blockade in Diastolic Heart Failure), published in the Journal of the American Medical Association, demonstrate that although the treatment works as expected to improve diastolic function in this patient population, no clinical benefits were observed in association with th...
Source: Forbes.com Healthcare News - February 26, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
Spironolactone disappoints in preserved-EF heart failure: Aldo-DHF in print
Aldosterone blockade didn't produce the outcomes that matter most to patients, despite one benefit in the 422-patient study that was at least encouraging. A large mortality trial is on the way. (Source: theHeart.org)
Source: theHeart.org - February 26, 2013 Category: Cardiology Source Type: news
Long-Term Use Of Medication May Improve Heart Function, But Does Not Improve Symptoms, Quality Of Life For Heart Failure Patients
Among patients with heart failure with preserved ejection fraction, long-term treatment with the medication spironolactone improved left ventricular diastolic function but did not affect maximal exercise capacity, patient symptoms, or quality of life, according to a study appearing in the February 27 issue of JAMA... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 26, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news
Heart Failure Drug May Only Help Heart's Function, Not Symptoms
Spironolactone didn't boost treadmill test results, quality of life in one form of condition, study finds
Source: HealthDay
Related MedlinePlus Page: Heart Failure (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 26, 2013 Category: Consumer Health News Source Type: news
Drug Has Mixed Results in Diastolic HF (CME/CE)
(MedPage Today) -- In patients with heart failure with preserved ejection fraction, spironolactone improved left ventricular diastolic function but did not affect clinical status, the Aldo-DHF trial showed. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - February 26, 2013 Category: Consumer Health News Source Type: news
Spironolactone Improves Diastolic Function in CHF, but Not Symptoms or Exercise Capacity
(Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 26, 2013 Category: Primary Care Tags: Medical News Source Type: news
Doubling down on RAAS blockade in HF? Aldosterone antagonists, not ARBs, says meta-analysis
For patients with symptomatic systolic heart failure on ACE inhibitors, further renin-angiotensin-aldosterone system suppression with spironolactone (or eplerenone) should help clinically with reasonable safety; the same can't be said for ARBs. (Source: theHeart.org)
Source: theHeart.org - December 24, 2012 Category: Cardiology Source Type: news
